April 18, 2024
Titan (ASX:TTM) shakes hands on Hancock buy-in to Ecuador copper
Titan’s confidence in a tier-1 copper asset gets a major backing from a Hancock subsidiary as the red metal continues to ascend.
Author: Jack Baker
April 18, 2024
Castile (ASX:CST) granted Major Project Status in Australia’s Top End
Major Project status opens government co-ordination and clears regulatory hurdles toward rapid development of a high-grade IOCG asset.
April 18, 2024
Diatreme (ASX:DRX) lifts silica sand mine confidence amid Queensland hub push
A confidence uplift moves Diatreme’s resource past an inflection point for mine planning at a potential silica hub in northern Queensland.
April 17, 2024
Turaco (ASX:TCG) tastes compelling first strikes from auric Afema on Ivory Coast
First drilling into a newly acquired asset returns striking gold results as Turaco looks toward a large maiden resource at an emerging flagship.
April 16, 2024
Nova (ASX:NVA) presents 5.17 million Alaskan ounces for US listing
Nova’s restrained SEC-required estimate shows less ounces, but a large gold-in-pit increase for an imminent US listing.
April 15, 2024
Aston (ASX:ASO) grows confidence in Canadian nickel-cobalt
A large confidence upgrade has Aston looking toward the technical for a move to mining on Ontario nickel-cobalt.
April 15, 2024
Ioneer (ASX:INR) to hit another lithium-boron milestone at Rhyolite Ridge in US
A Rhyolite Ridge redesign around an endangered species takes Ioneer another step closer to production and its place in an ascendant US industry.
April 10, 2024
Forrestania (ASX:FRS) grabs high-grade taste of Eastern Goldfields
High-grade grabs and historic strikes in premium gold territory ups the Ada Ann prospect’s exploration potential for a maiden campaign.
April 10, 2024
Argenica (ASX:AGN) doses first 5 stroke patients with no adverse events
Five patients have now safely been dosed and Argenica marks another milestone in pivotal second phase trials in the battle against stroke.
April 10, 2024
The virtue of patients
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.